GleamWall
中文EN

CTKB Cytek Biosciences, Inc.

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1831915 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.5%
TTM net income YoY-533.4%
TTM EPS YoY-519.7%
Revenue 3-yr CAGR4.3%
Net income 3-yr CAGR—

Margins

Gross margin54.7%
Operating margin-21.1%
Net margin-39.1%
FCF margin-6.5%
EBITDA margin-18.2%

Returns

ROE-23.2%
ROA-17.3%
ROIC (approx.)-12.8%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets28.0%
Debt / equity0.00x
Current ratio4.46x
Interest coverage-562.56x

Cash quality & payout

Operating cash flow / net income0.08x
Accruals ratio-15.9%
Payout ratio—
Capex / revenue3.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$53.23M$48.14M$44.13M$62.14M$52.29M$45.60M$41.46M$57.48M
Cost of revenue$22.02M$19.80M$22.88M$29.26M$24.74M$21.73M$21.30M$23.82M
Gross profit$31.21M$28.34M$21.25M$32.88M$27.55M$23.87M$20.16M$33.65M
R&D expense$9.36M$9.74M$9.60M$8.96M$8.96M$8.83M$9.72M$9.72M
SG&A expense$18.36M$16.82M$18.47M$16.39M$16.12M$13.53M$12.90M$9.07M
Operating income-$8.42M-$11.40M-$18.46M-$5.59M-$9.19M-$10.62M-$14.97M$2.99M
Interest expense$260,000$281,000$262,000-$725,000$494,000$414,000$291,000-$5.93M
Pretax income———-$4.03M-$7.77M-$6.78M-$11.27M$10.32M
Income tax-$811,000$515,000$1.49M$40.05M-$2.29M-$1.19M$136,000$680,000
Net income-$6.10M-$12.16M-$18.87M-$44.08M-$5.48M-$5.58M-$11.40M$9.64M
EBITDA-$7.22M-$10.30M-$16.60M-$3.70M-$8.19M-$9.62M-$13.10M$4.84M
EPS (diluted)————————
Weighted avg. shares (diluted)130.36M129.46M128.70M—127.55M126.93M128.34M—
Balance sheet
Cash & equivalents$66.81M$73.85M$65.67M$90.85M$93.28M$75.47M$95.30M$98.75M
Receivables$59.19M$49.70M$51.90M$62.51M$56.63M$56.23M$55.03M$60.59M
Inventory$52.37M$52.25M$49.79M$48.43M$51.65M$49.49M$45.35M$43.89M
Current assets$378.94M$377.93M$379.30M$392.00M$388.49M$382.82M$380.50M$396.45M
PP&E, net$20.61M$20.80M$20.47M$18.01M$18.05M$18.35M$17.83M$17.96M
Goodwill$16.69M$16.69M$16.69M$16.70M$16.70M$16.71M$16.68M$16.66M
Intangibles$14.03M$14.87M$15.70M$16.82M$17.68M$18.60M$19.43M$20.13M
Total assets$446.14M$446.93M$449.11M$461.54M$494.92M$493.32M$482.60M$499.50M
Current liabilities$84.95M$84.33M$80.94M$77.80M$75.21M$73.27M$67.69M$67.66M
Total liabilities$124.79M$124.98M$121.47M$119.80M$116.35M$115.76M$102.97M$103.76M
Shareholders' equity$321.35M$321.95M$327.64M$341.74M$378.57M$377.56M$379.62M$395.74M
Shares outstanding130.77M129.98M129.14M128.55M127.86M127.19M127.60M129.21M
Cash flow statement
Operating cash flow-$4.45M$1.37M-$2.74M-$771,000-$3.90M$108,000-$125,000$2.00M
Capital expenditure$1.51M$2.22M$2.17M$1.00M$657,000$1.58M$849,000$894,000
Free cash flow-$5.96M-$849,000-$4.90M-$1.77M-$4.55M-$1.47M-$974,000$1.10M
Investing cash flow-$1.80M$7.02M-$27.08M-$1.84M$18.92M-$16.41M$9.45M-$63.43M
Financing cash flow-$561,000-$814,000$3.98M-$1.23M$1.94M-$2.60M-$11.54M-$3.64M
Depreciation & amortization$1.20M$1.10M$1.86M$1.90M$1.00M$1.00M$1.88M$1.85M
Stock-based compensation$4.85M$5.34M$4.86M$5.53M$5.64M$6.79M$6.63M$7.00M
Share buybacks$0$0$0-$34,000-$29,000$4.51M$10.63M$7.00M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.